相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。GPCR Inhibition in Treating Lymphoma
Marilia Barreca et al.
ACS MEDICINAL CHEMISTRY LETTERS (2022)
Insight on [1,3]thiazolo[4,5-e]isoindoles as tubulin polymerization inhibitors
Virginia Spano et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance
Zhijie Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein
Virginia Spano et al.
MOLECULES (2021)
Discovery of a Potent and Selective FLT3 Inhibitor (Z)-N-(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1H-pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia
Junwei Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Identification of Thieno[3,2-d]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3
Hanna Cho et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
Ahmad I. Antar et al.
LEUKEMIA (2020)
An overview on anti-tubulin agents for the treatment of lymphoma patients
Marilia Barreca et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma
A. Arribas et al.
EUROPEAN JOURNAL OF CANCER (2020)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
Discovery of the selective and efficacious inhibitors of FLT3 mutations
Yanle Zhi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations
Takeshi Yamaura et al.
BLOOD (2018)
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
Maria Larrosa-Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma
Virginia Spano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
A Comparative Docking Strategy to Identify Polyphenolic Derivatives as Promising Antineoplastic Binders of G-quadruplex DNA c-myc and bcl-2 Sequences
Giosue Costa et al.
MOLECULAR INFORMATICS (2016)
Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification
Yi-Yu Ke et al.
SCIENTIFIC REPORTS (2015)
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
Richard F. Schlenk et al.
BLOOD (2014)
Synthesis of [1,2]oxazolo[5,4-e]indazoles as antitumour agents
Paola Barraja et al.
TETRAHEDRON (2013)
First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
Josep Tabernero et al.
CANCER DISCOVERY (2013)
Synthesis and Antiproliferative Activity of the Ring System [1,2]Oxazolo[4,5-g]indole
Paola Barraja et al.
CHEMMEDCHEM (2012)
Improving the Prediction of Absolute Solvation Free Energies Using the Next Generation OPLS Force Field
Devleena Shivakumar et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2012)
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Li Ding et al.
NATURE (2012)
Synthesis of pyrrolo[3,2-h]quinolinones with good photochemotherapeutic activity and no DNA damage
Paola Barraja et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
Keith W. Pratz et al.
BLOOD (2010)
Pyrano[2,3-e]isoindol-2-ones, new angelicin heteroanalogues
Paola Barraja et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Synthesis of the new ring system 6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline
Paola Barraja et al.
TETRAHEDRON LETTERS (2009)
Mutant FLT3:: A direct target of sorafenib in acute myelogenous leukemia
Weiguo Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Aryl nitro reduction with iron powder or stannous chloride under ultrasonic irradiation
Allan B. Gamble et al.
SYNTHETIC COMMUNICATIONS (2007)
FLT3 tyrosine kinase inhibitors
M Levis et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
Targeting FLT3 kinase in acute myelogenous leukemia: Progress, perils, and prospects
MC Heinrich
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2004)
Flt3 receptor tyrosine kinase as a drug target in leukemia
D Schmidt-Arras et al.
CURRENT PHARMACEUTICAL DESIGN (2004)
The role of FLT3 in haematopoietic malignancies
DL Stirewalt et al.
NATURE REVIEWS CANCER (2003)
FLT3 mutations in acute myeloid leukemia cell lines
H Quentmeier et al.
LEUKEMIA (2003)
Receptor tyrosine kinase signalling as a target for cancer intervention strategies
E Zwick et al.
ENDOCRINE-RELATED CANCER (2001)
Short tandem repeat profiling provides an international reference standard for human cell lines
JR Masters et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Monitoring of cell viability and cell growth in a hollow-fiber bioreactor by use of the dye Alamar Blue™
H Gloeckner et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2001)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling
SL Zhang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
